Abstract 1066P
Background
Previous data suggest a negative impact of steroids (ST) in patients (pts) treated with immune checkpoint inhibitors (ICI), due to their immunosuppressive properties. How dosage and time of administration modulate this effect is yet to be clarified.
Methods
Retrospective study of pts who received ICI alone in a tertiary university hospital (2016-2022). For each pt, the daily dose of ST was collected (equivalent in mg/kg of prednisone) until progression of disease (PD) or death: 30 days before the 1st cycle (C1) (-30D), 30 days from C1 (D1-30), 3 months from C1 (D1-90) and after 6 months (m) from C1 (>D6m). We evaluated the impact of the cumulative dose (CD) of ST on the objective response rate (ORR), the disease control rate (DCR) and progression-free survival (PFS).
Results
We evaluated 475 pts (median age: 67.5) with advanced solid tumors (NSCLC: 33.9%; urothelial: 17.3%; renal: 13.7%; melanoma: 11.2%; head and neck: 11.0%; others: 12.9%) treated with anti-PD1 (64.4%), anti-PDL1 (20.4%), anti-PD1 plus anti-CTLA4 (13.3%) or anti-CTLA4 (1.9%); 42.1% in 1st line, 43.1% in 2nd line, 14.8% in further lines. Performance status (PS) prior to C1 was: 0 (31.0%), 1 (53.6%), ≥2 (15.4%). 48.2% of pts received ST during therapy with ICI (17.3% in -30D; 32.6% in D1-D90; 16.6% in >D6m). The ORR was significantly lower in pts who received ST in -30D (20.3% [95% CI 11.4-29.1%] vs 36.7% [95% CI 31.8-41.5%]; p<0.01) and in D1-90 (25.7% [95% CI 18.6-32.7%] vs 37.7% [95% CI 32.3-43.1%; p=0.01]). The negative impact of ST was confirmed by a multivariate analysis including PS, type of tumor, disease burden, type of ICI and line of treatment. There was an inverse correlation between the CD of ST in -30D and the DCR (no ST: 52.1%; Q1: 45%; Q2: 30.0%; Q3: 15.8%; Q4: 25%) (p<0.01). The impact of CD was confirmed in D1-30, but not in D1-90 and >D6m. Among pts without PD at 6 months, PFS tended to be longer in those who received ST (23.2 vs 17.6 m; p=0.065).
Conclusions
Our results demonstrate the negative impact of ST on the outcomes of ICI, even at low doses. This effect seems time and dose-dependent, prevailing in pts with an early exposure to ST (<3m) and proportional to cumulative dose only around the initiation of ICI (from -30D to D30).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
A. Soria Rivas: Financial Interests, Institutional, Advisory Board: MSD, Novartis, Bristol, Roche, Merck, Sanofi Aventis. P. Garrido Lopez: Financial Interests, Institutional, Advisory Board: AstraZeneca, Bristol, Janssen, Lilly, Pfizer, Roche, Novartis, Rovi, Gilead, MSD, Takeda. P. Gajate Borau: Financial Interests, Institutional, Advisory Board: Astellas, Bristol Myers, Ipsen, Merck, Ipsen, Pfizer, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
1037P - Phase I dose-escalation trial with tumor-targeted interleukin-12 (IL12-L19L19) in patients with solid tumors
Presenter: Nicolas Mach
Session: Poster session 19
1039P - First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors
Presenter: Geoffrey Ku
Session: Poster session 19
1040P - Phase I study of IL-8 inhibitor AMY109 plus atezolizumab (atezo) in patients (pts) with advanced solid tumours
Presenter: Yasutoshi Kuboki
Session: Poster session 19
1041P - Phase I open-label, dose escalation and expansion study of YH003, an anti-CD40 agonist monoclonal antibody in combination with toripalimab in patients (pts) with advanced solid tumours
Presenter: Ben Markman
Session: Poster session 19
1042P - INSIGHT 003 evaluating feasibility of eftilagimod alpha (soluble LAG-3) combined with first-line chemo-immunotherapy in metastatic non-small cell lung cancer (NSCLC) adenocarcinomas
Presenter: Akin Atmaca
Session: Poster session 19
1043P - First-in-human study of TU2218, TGFβRI and VEGFR2 dual inhibitor in patients with advanced solid tumors
Presenter: Do-Youn Oh
Session: Poster session 19
1044P - A phase Ia first-in-human study of JS007, a novel anti-CTLA-4 monoclonal antibody, in patients with advanced solid tumors
Presenter: Jun Zhang
Session: Poster session 19
1045P - Safety and preliminary clinical activity of JNJ-78306358 (JNJ-358), an HLA-G and CD3 bispecific antibody, for the treatment of advanced stage solid tumor
Presenter: Ravit Geva
Session: Poster session 19
1046P - Phase I/II open-label study on an anti-GPC3 T cell engager, SAR444200, in patients with advanced solid tumors: Preliminary dose escalation results
Presenter: Jung Yong Hong
Session: Poster session 19